Trevi Therapeutics
  • Our Science
    • Haduvio™
    • Publications
    • Partnering
  • Pipeline & Clinical Trials
    • Pipeline
    • Previous Clinical Trials
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Stock Price
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Board Committees
    • Investor Resources
      • Investor FAQs
      • Investor Contacts
      • Investor Alerts
  • About Us
    • Leadership
    • Board of Directors
    • Commitment to Patients
    • Life at Trevi
    • Benefits
    • Careers
  • Contact
Select Page

news

Trevi Therapeutics to Participate in Upcoming September Conferences

08/28/2025

Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

08/07/2025

Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025

07/31/2025

VIEW ALL NEWS

contact

Trevi Therapeutics

195 Church Street, 16th Floor
New Haven, CT 06510
map

(203) 304-2499
email us

  • U.S. Website Privacy Notice
  • GDPR Data Protection Notice
  • Terms of Use
  • Twitter
  • Linkedin
Haduvio (nalbuphine ER) is an investigational therapy and not yet approved for use in any indication.
© 2025 Trevi Therapeutics, All Rights Reserved. Terms of Service. Website by D&CO